Skip to main content

Table 1 Baseline demographics and clinical characteristics for TN patients with CC, GT1–6a treated with 8-week G/P

From: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Characteristic Global PMOS (N = 12) DHC-R (N = 20) Scottish HCV (N = 24) Italian MISTRAL (N = 11) Italian NAVIGATORE (N = 3) US TRIO (N = 73) US VA (N = 85)
Male 6 (50.0) 9 (45.0) 24 (100) 6 (54.5) 1 (33.3) 44 (60.3) 83 (97.6)
Age, median (range), years 56 (25–80) 59.5, 47.5 (33–81)b 48.2 (40–70; 11.6c) 70 (37–85) 66 (51–71) 59 (31–76) 64.7 (49–85)
Genotype
 GT1 3 (25.0) 11 (55.0) 23 (95.8) 5 (45.5) 0 59 (80.8) 71 (83.5)
 GT2 3 (25.0) 1 (5.0) 0 6 (54.5) 2 (67.3) 7 (10.0) 10 (11.8)
 GT3 5 (41.7) 6 (30.0) 0 0 0 4 (5.5) 4 (4.7)
 GT4–6 1 (8.3) 2 (10.0) 1 (4.2) 0 1 (33.3) 3 (4.1) 0
 Missing 0 0 0 0 0 0 0
Fibrosis score
 F0–1 1 (8.3)d 0 0 0 0 0 N/A
 F2 2 (16.7)d 0 0 0 0 0 N/A
 F3 0 0 0 0 0 0 N/A
 F4 4 (33.3)d 20 24 (100) 11 (100) 3 (100) 73 (100) N/A
 Missing 5 0 0 0 0 0 N/A
FibroScan®, median (range) 15.5 (8.5–21.6) N/A 24.1 (11.6–54.2) 14.1 (13.1–20) N/A N/A N/A
Child–Pugh
 A (5) 10 (83.3) 7 (35.0) 15 (62.5) 11 (100) 3 (100)e 73 (100)e N/A
 A (6) 0 0 8 (33.3) 0 N/A
 B (7) 0 0 1 (4.2) 0 0 0 N/A
 Missing 2 13 0 0 0 0 N/A
Bilirubin, median (range), mg/dL 0.7 (0.17–1.7) 0.7, 0.5 (0.2–1.4)b 1.4 (0.3–3.3) 0.70 (0.30–1.10) 1.0 (0.9–1.1) N/A N/A
Albumin, median (range), g/dL 4.1 (3.8–5.1) 4.3, 4.0 (3.2–5.6)b 3.7 (3.0–4.3; 5.0c) 3.8 (3.6–4.1) 2.9 (2.7–3.0) N/A 3.9 (2.4–4.8)
Albumin ≥ 3.5, g/dL 6 (50.0) 8 (25.0) 17 (70.8) 11 (100) 0 N/A N/A
Platelets, median (range), μL 157,500 (52,000–286,000) 185,000, 198,000 (118,000–381,000)b 149f (36–206; 105c) 183,000 (88,000–260,000) 137f (85–338) N/A 198f (82–395)
Platelets < 90,000 μL 2 (16.7) 0 2 (8.3) 1 (9.1) N/A N/A 1 (1.2)
PWUD status
 Yes 1 (8.3) 1 (5.0)g 21 (87.5)h 0 0 N/A N/A
 No 10 (83.3) 19 (95.0) 3 (12.5)h 11 (100) 3 (100) N/A N/A
 Missing 1 0 0 0 0 N/A N/A
Comorbidities
 Current alcohol use 5 (41.7) 2 (10.0) N/A 0 0 N/A 24 (28.2)i
 Psychiatric disease 1 (8.3) 3 (15.0) N/A 0 0 N/A 70 (82.4)
 HIV coinfection 1 (8.3) 0 1 (4.2) 0 1 (33.3) 1 (1.4) 2 (2.4)
  1. Data: n (%) unless otherwise stated. FibroScan® is a product of Echosens (Waltham, MA)
  2. CC compensated cirrhosis, G/P glecaprevir/pibrentasvir, GT genotype, HCV hepatitis C virus, PMOS post-marketing observational studies, PWUD people who use drugs, TN treatment-naïve, VA Veterans Association
  3. aScottish HCV study included GT1,2,4–6, US VA study included GT1–3
  4. bData: GT1,2,4–6 median, GT3 median (GT1–6 range)
  5. cInterquartile range
  6. dFibrosis status was determined by the site
  7. eChild–Pugh A (5–6)
  8. fPlatelets, count
  9. gActive drug use
  10. hInjection drug use as a risk factor for HCV, active status unknown
  11. iAlcohol use in the past year